Current Document Type: HighlightsVideoPage Multiple Myeloma Patient-Reported Experiences With Belantamab Mafodotin - JADPRO

Watch More Highlights

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses key insights for advanced practitioners from the DREAMM-2 study, which detailed the self-reported experiences of patients with relapsed or refractory multiple myeloma who had treatment-related side effects from belantamab mafodotin (Abstract 3248).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.